* Alnylam Pharmaceuticals Inc reported a quarterly adjusted loss of 52 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-1.40. The mean expectation of twenty five analysts for the quarter was for a loss of $1.18 per share. Wall Street expected results to range from $-1.56 to -27 cents per share.
* Revenue rose 54.8% to $494.33 million from a year ago; analysts expected $427.33 million.
* Alnylam Pharmaceuticals Inc's reported EPS for the quarter was a loss of 52 cents.
* The company reported a quarterly loss of $65.94 million.
* Alnylam Pharmaceuticals Inc shares had risen by 0.3% this quarter and lost 21.7% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 9.4% in the last three months.
* In the last 30 days, two analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 9 "hold" and no "sell" or "strong sell."
* Wall Street's median 12-month price target for Alnylam Pharmaceuticals Inc is $221.00
This summary was machine generated from LSEG data May 2 at 01:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -1.18 -0.52 Beat
Dec. 31 2023 -1.32 -1.10 Beat
Sep. 30 2023 -1.34 1.15 Beat
Jun. 30 2023 -1.37 -2.21 Missed
Comments